Exemplary data: sample size and power in the design of event-time clinical trials.

In planning a complex clinical trial with time to event as the outcome, it is difficult to derive the power of the test statistic analytically. In this paper we describe an algorithm for generating exemplary data from an alternative hypothesis that can be used to compute the expected value of a logrank test statistic and its power under that alternative. Exemplary data are nonrandomly computer-generated data that are constructed from a complex stochastic process and have desirable characteristics such as distributional moments similar to those of the process. An algorithm for generating exemplary timed events data is presented and its use in evaluating power for the planning of clinical trials demonstrated. These data represent "expectations" of outcome, data censoring, and censoring event times. A test statistic, z, such as the logrank can be computed from the data. It is distributed asymptotically, N(mu A, 1), under the alternative hypothesis and its value is used to estimate mu A and the power of the test for a given trial scenario. The results compare favorably to results from analytical methods and Monte Carlo simulations published in the literature. The advantages of the method lie in the degree of flexibility in study design, choice of models that describe the timing of events, and the range of testing methods that can be used. Although Monte Carlo methods may appear to have similar flexibility, the exemplary algorithm is more practical because only one data set need be analyzed and the modifications can be achieved without reprogramming.

[1]  W. Deming,et al.  On a Least Squares Adjustment of a Sampled Frequency Table When the Expected Marginal Totals are Known , 1940 .

[2]  A I Goldman,et al.  Survivorship analysis when cure is a possibility: a Monte Carlo study. , 1984, Statistics in medicine.

[3]  B. Pasternack,et al.  Planning the duration of long-term survival time studies designed for accrual by cohorts. , 1971, Journal of chronic diseases.

[4]  D. Schoenfeld The asymptotic properties of nonparametric tests for comparing survival distributions , 1981 .

[5]  D. Cox Regression Models and Life-Tables , 1972 .

[6]  J. Lachin Introduction to sample size determination and power analysis for clinical trials. , 1981, Controlled clinical trials.

[7]  M H Gail,et al.  Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. , 1981, Journal of chronic diseases.

[8]  J Halpern,et al.  Designing clinical trials with arbitrary specification of survival functions and for the log rank or generalized Wilcoxon test. , 1987, Controlled clinical trials.

[9]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[10]  Frederick Mosteller,et al.  Association and Estimation in Contingency Tables , 1968 .

[11]  Joseph Berkson,et al.  Survival Curve for Cancer Patients Following Treatment , 1952 .

[12]  S. George,et al.  Planning the size and duration of a clinical trial studying the time to some critical event. , 1974, Journal of chronic diseases.

[13]  E. Lakatos,et al.  Sample sizes based on the log-rank statistic in complex clinical trials. , 1988, Biometrics.

[14]  E. Eaker,et al.  Risk factor screening and intervention: a psychological/behavioral cost or a benefit? , 1981, Controlled clinical trials.

[15]  Stephen E. Fienberg,et al.  Discrete Multivariate Analysis: Theory and Practice , 1976 .